A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration

被引:26
|
作者
Sime, Fekade B. [1 ,2 ]
Lassig-Smith, Melissa [3 ]
Starr, Therese [3 ]
Stuart, Janine [3 ]
Pandey, Saurabh [1 ]
Parker, Suzanne L. [1 ]
Wallis, Steven C. [1 ]
Lipman, Jeffrey [1 ,3 ,4 ]
Roberts, Jason A. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Queensland, Ctr Clin Res, Fac Med, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Sch Pharm, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[4] Univ Montpellier, Nimes Univ Hosp, Div Anaesthesiol Crit Care Emergency & Pain Med, Nimes, France
[5] Royal Brisbane & Womens Hosp, Pharm Dept, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
ceftolozane-tazobactam; pharmacokinetics; renal replacement therapy; hemodiafiltration; CRRT; RENAL REPLACEMENT THERAPY; PSEUDOMONAS-AERUGINOSA; CLEARANCE;
D O I
10.1128/AAC.01655-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aim of this work was to describe optimized dosing regimens of ceftolozane-tazobactam for critically ill patients receiving continuous venovenous hemodiafiltration (CVVHDF). We conducted a prospective observational pharmacokinetic study in adult critically ill patients with clinical indications for ceftolozane-tazobactam and CVVHDF. Unbound drug concentrations were measured from serial prefilter blood, postfilter blood, and ultrafiltrate samples by a chromatographic assay. Population pharmacokinetic modeling and dosing simulations were performed using Pmetrics. A four-compartment pharmacokinetic model adequately described the data from six patients. The mean (+/- standard deviation [SD]) extraction ratios for ceftolozane and tazobactam were 0.76 +/- 0.08 and 0.73 +/- 0.1, respectively. The mean +/- SD sieving coefficients were 0.94 +/- 0.24 and 1.08 +/- 0.30, respectively. Model-estimated CVVHDF clearance rates were 2.7 +/- 0.8 and 3.0 +/- 0.6 liters/h, respectively. Residual non-CVVHDF clearance rates were 0.6 +/- 0.5 and 3.3 +/- 0.9 liters/h, respectively. In the initial 24 h, doses as low as 0.75 g every 8 h enabled cumulative fractional response of >= 85% for empirical coverage against Pseudomonas aeruginosa, considering a 40% fT (>MIC) (percentage of time the free drug concentration was above the MIC) target. For 100% fT (>MIC), doses of at least 1.5 g every 8 h were required. The median (interquartile range) steady-state trough ceftolozane concentrations for simulated regimens of 1.5 g and 3.0 g every 8 h were 28 (21 to 42) and 56 (42 to 84) mg/liter, respectively. The corresponding tazobactam concentrations were 6.1 (5.5 to 6.7) and 12.1 (11.0 to 13.4) mg/liter, respectively. We suggest a front-loaded regimen with a single 3.0-g loading dose followed by 0.75 g every 8 h for critically ill patients undergoing CVVHDF with study blood and dialysate flow rates.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients
    Ibrahim El-Haffaf
    Romain Guilhaumou
    Lionel Velly
    Amélie Marsot
    Clinical Pharmacokinetics, 2022, 61 : 895 - 906
  • [42] Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients
    El-Haffaf, Ibrahim
    Guilhaumou, Romain
    Velly, Lionel
    Marsot, Amelie
    CLINICAL PHARMACOKINETICS, 2022, 61 (06) : 895 - 906
  • [43] Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients With Acute Kidney Injury Treated With Continuous Hemodiafiltration
    Niibe, Yoko
    Suzuki, Tatsuya
    Yamazaki, Shingo
    Suzuki, Takaaki
    Takahashi, Nozomi
    Hattori, Noriyuki
    Nakada, Taka-aki
    Oda, Shigeto
    Ishii, Itsuko
    THERAPEUTIC DRUG MONITORING, 2020, 42 (04) : 588 - 594
  • [44] A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01)
    Kalaria, Shamir N.
    Armahizer, Michael
    McCarthy, Paul
    Badjatia, Neeraj
    Gobburu, Jogarao, V
    Gopalakrishnan, Mathangi
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (05): : 950 - 959
  • [45] Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    Schatz, Lea Marie
    Brinkmann, Alexander
    Roehr, Anka
    Frey, Otto
    Greppmair, Sebastian
    Weinelt, Ferdinand
    Zoller, Michael
    Scharf, Christina
    Hempel, Georg
    Liebchen, Uwe
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (05)
  • [46] Copper, selenium, zinc, and thiamine balances during continuous venovenous hemodiafiltration in critically ill patients
    Berger, MM
    Shenkin, A
    Revelly, JP
    Roberts, E
    Cayeux, MC
    Baines, M
    Chioléro, RL
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2004, 80 (02): : 410 - 416
  • [47] Continuous venovenous hemofiltration versus continuous venovenous hemodiafiltration in critically ill patients: A retrospective cohort study from a Canadian tertiary centre
    AlEnezi, Farhan
    Alhazzani, Waleed
    Ma, Jinhui
    Alanazi, Safug
    Salib, Mary
    Attia, Menat
    Thabane, Lehana
    Fox-Robichaud, Alison
    CANADIAN RESPIRATORY JOURNAL, 2014, 21 (03) : 176 - 180
  • [48] Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration
    Ververs, TFT
    van Dijk, A
    Vinks, SATMM
    Blankestijn, PJ
    Savelkoul, TJF
    Meulenbelt, J
    Boereboom, FTJ
    CRITICAL CARE MEDICINE, 2000, 28 (10) : 3412 - 3416
  • [49] VARIABLE DISPOSITION OF CIPROFLOXACIN IN CRITICALLY ILL PATIENTS UNDERGOING CONTINUOUS ARTERIOVENOUS HEMODIAFILTRATION
    FISH, DN
    BAINBRIDGE, JL
    PELOQUIN, CA
    PHARMACOTHERAPY, 1995, 15 (02): : 236 - 245
  • [50] Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model
    Minichmayr, Iris K.
    Roberts, Jason A.
    Frey, Otto R.
    Roehr, Anka C.
    Kloft, Charlotte
    Brinkmann, Alexander
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (05) : 1330 - 1339